Literature DB >> 12684512

Human prorenin has "gate and handle" regions for its non-proteolytic activation.

Fumiaki Suzuki1, Makoto Hayakawa, Tsutomu Nakagawa, Uddin Mohammad Nasir, Akio Ebihara, Atsushi Iwasawa, Yuichi Ishida, Yukio Nakamura, Kazuo Murakami.   

Abstract

We investigated the mechanism for non-proteolytic activation of human prorenin using five kinds of antibodies. Each of the antigens, L1PPTDTTTFKRI11P, T7PFKRIFLKRMP17P, I11PFLKRMPSIRESLKER26P, M16PPSIRESLKER26P, and G27PVDMARLGPEWSQPM41P, was designed from the tertiary structure of predicted prorenin. These antibodies were labeled anti-01/06, anti-07/10, anti-11/26, anti-16/26, and anti-27/41, respectively, for their binding specificities. Inactive recombinant human prorenin (0.1 nM) bound to various concentrations of anti-01/06, anti-11/26, and anti-27/41 antibodies at 4 degrees C with equilibrium dissociation constants of 138, 41, and 22 nM, respectively. However, intact prorenin (0.1 nM) did not show significant binding to 200 nM anti-07/10 and anti-16/26 antibodies for 20 h. Ninety percent of prorenin (0.1 nM) was found to be non-proteolytically activated by incubation with anti-11/26 antibodies (200 nM) at 4 degrees C for 20 h. Prorenin was not active even under complex with either anti-01/06 or anti-27/41 antibodies. Prorenin was also reversibly activated at pH 3.3 and 4 degrees C for 25 h. The acid-activated prorenin bound to anti-07/10 and anti-16/26 antibodies as well as to anti-01/06, anti-11/15, and anti-27/41 antibodies at neutral pH and 4 degrees C in 2 h. Their dissociation constants were 13, 40, 8.6, 3.6, and 14 nM, respectively. The acid-activated prorenin was re-inactivated by incubation at pH 7.4 and 4 degrees C in 50 h. Anti-07/10 and anti-11/26 antibodies inhibited such re-inactivation at 25 degrees C by more than 90% and 50%, respectively, whereas other kinds of antibodies did not prevent the re-inactivation at 25 degrees C. These results indicate that prorenin has "gate" (T7PFKR10P) and "handle" (I11PFLKR15P) regions critical for its non-proteolytic activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684512     DOI: 10.1074/jbc.M302579200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay.

Authors:  H Yokota; F Mori; K Kai; T Nagaoka; N Izumi; A Takahashi; T Hikichi; A Yoshida; F Suzuki; Y Ishida
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

2.  Renin and cardiovascular disease: Worn-out path, or new direction.

Authors:  Gaurav Alreja; Jacob Joseph
Journal:  World J Cardiol       Date:  2011-03-26

Review 3.  Prorenin/renin receptor, signals, and therapeutic efficacy of receptor blocker in end-organ damage.

Authors:  Tadashi Inagami; Atsuhiro Ichihara
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

Review 4.  Prorenin and the (pro)renin receptor in ocular pathology.

Authors:  Jennifer L Wilkinson-Berka
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

Review 5.  The potential role of the angiotensin subtype 2 receptor in cardiovascular protection.

Authors:  Helmy M Siragy
Journal:  Curr Hypertens Rep       Date:  2009-08       Impact factor: 5.369

Review 6.  Direct renin inhibition and the kidney.

Authors:  Norman K Hollenberg
Journal:  Nat Rev Nephrol       Date:  2009-11-24       Impact factor: 28.314

7.  Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.

Authors:  Atsuhiro Ichihara; Matsuhiko Hayashi; Yuki Kaneshiro; Fumiaki Suzuki; Tsutomu Nakagawa; Yuko Tada; Yukako Koura; Akira Nishiyama; Hirokazu Okada; M Nasir Uddin; A H M Nurun Nabi; Yuichi Ishida; Tadashi Inagami; Takao Saruta
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  Aliskiren reduces the release of soluble (pro)renin receptor from human umbilical vein endothelial cells.

Authors:  Shinji Yamashita; Kazal Boron Biswas; A H M Nurun Nabi; Tsutomu Nakagawa; Fumiaki Suzuki; Akio Ebihara
Journal:  Biomed Rep       Date:  2018-07-05

Review 9.  What is the role of renin inhibition in the treatment of diabetic kidney disease?

Authors:  Radko Komers
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

10.  (Pro)renin receptor: a treatment target for diabetic retinopathy?

Authors:  Jennifer L Wilkinson-Berka; Duncan J Campbell
Journal:  Diabetes       Date:  2009-07       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.